Press release
Novartis' Radioligand Therapies Pipeline and Strategic Acquisitions: Key Drivers Behind Radioligand Therapies Market Exponential Growth Through 2034 | DelveInsight
Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
DelveInsight's report, "Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 [https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides in-depth analysis of radioligand therapies market dynamics, epidemiology trends, and emerging technologies that will shape the future of radioligand therapies, which is transforming cancer treatment paradigms across multiple oncology indications.
Radioligand therapy works through a sophisticated mechanism that delivers targeted radiation directly to tumor sites. The process begins by identifying specific proteins overexpressed on cancer cell surfaces, then developing targeting molecules (ligands) attached to radioactive isotopes. These are administered intravenously and bind to target proteins on cancer cells, delivering localized radiation that damages the DNA of cancer cells while minimizing exposure to healthy tissues. Therapeutic radioisotopes are produced in special nuclear reactors or generators, then shipped to production facilities where they are bonded to cell-targeting compounds, creating ready-to-use therapies that can be administered in hospital or clinic settings.
The radioligand therapy landscape has seen substantial clinical progress since 2018, when the FDA approved LUTATHERA, manufactured by Novartis, as the first radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). LUTATHERA's success has been remarkable, with sales exceeding USD 450 million in the first nine months of 2023 alone, representing a 34% year-over-year growth.
Stay informed on the latest FDA approvals @ Radioligand Therapies FDA Approvals [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Novartis projects peak sales could surpass USD 1 billion as it expands into first-line therapy. In a significant milestone for pediatric oncology, LUTATHERA received FDA approval in 2024 as the first medicine specifically for pediatric patients with GEP-NETs, broadening its therapeutic reach to younger patient populations with these rare tumors.
The market's expansion accelerated in 2022 with the FDA's approval of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), also developed by Novartis (SWX: NOVN), for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. PLUVICTO demonstrated impressive commercial performance, generating approximately USD 980 million in sales during its first full year, narrowly missing blockbuster status.
Explore ongoing and upcoming clinical trials driving innovation in radioligand therapies @ Radioligand Therapies Clinical Trials [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Other established radioligand therapies include Bayer's XOFIGO (radium ra-223 dichloride) for castration-resistant prostate cancer with symptomatic bone metastases, and Spectrum Pharmaceuticals' ZEVALIN (ibritumomab tiuxetan) for relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.
The industry has witnessed significant strategic movements throughout 2023-2024, highlighting the growing importance of radioligand therapies in oncology portfolios. In March 2024, AstraZeneca (LON: AZN) acquired Fusion Pharmaceuticals (NASDAQ: FUSN) for USD 2 billion to accelerate the development of next-generation radioconjugates, bringing new expertise and pioneering R&D in actinium-based radioconjugates to enhance their cancer treatment pipeline. Furthermore, in May 2024, Novartis acquired Mariana Oncology, a cancer RLT-focused biotech, for USD 1 billion upfront with potential additional payments of up to USD 750 million upon milestone completion.
In December 2023, Eli Lilly completed its acquisition of Point Biopharma for approximately USD 1.4 billion, gaining ownership of Point's lead asset PNT2002, a radioligand therapy targeting PSMA for metastatic castration-resistant prostate cancer. Additionally, January 2024 saw two significant operational developments: the FDA's approval of Novartis's new automated radioligand therapy production plant for PLUVICTO, and InHealth's launch of the UK's first relocatable radioligand therapy service, enhancing treatment accessibility.
Discover evolving trends in the radioligand therapies landscape @ Radioligand Therapies Recent Developments [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The radioligand therapy pipeline continues to expand with several promising candidates advancing through clinical development. Curium US (NASDAQ: CURI) is developing 177Lu-PSMA-I&T, currently in phase III ECLIPSE trial (NCT05146973), which targets prostate-specific membrane antigen. Eli Lilly (NYSE: LLY) and Point Biopharma (NASDAQ: PNT) are advancing Lu-PNT2002, a PSMA-targeted lutetium-177-based radioligand therapy currently in phase III SPLASH trial (NCT04647526) combines PSMA-I&T with the beta-emitting radioisotope no-carrier-added lutetium-177.
Other pipeline candidates include Fusion Pharmaceuticals' FPI-2265 in Phase II/III studies, Lantheus (NASDAQ: LNTH) and Eli Lilly's LNTH-1095, Novartis's 225Ac-PSMA-R2, and Bayer's 225Ac-PSMATrillium, all targeting various stages of prostate cancer and poised to expand treatment options in the coming years.
The market's growth trajectory is supported by increasing cancer diagnosis rates, growing awareness of radioligand therapy's benefits, expanding clinical trial activity, and major pharmaceutical companies' increasing interest in this therapeutic space. With Novartis already having two RLTs available globally, numerous candidates in its pipeline, and several clinical trials underway or planned, the radioligand therapy market is positioned for sustained expansion.
Download the Radioligand Therapy Market Forecast Report to understand which factors are driving the Radioligand Therapy market @ Radioligand Therapy Market Trends [https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
As more data becomes available from ongoing clinical trials and new applications are discovered for conditions beyond the current indications of neuroendocrine tumors and prostate cancer, radioligand therapy is expected to become an increasingly integral component of cancer treatment protocols, further driving market growth and improving outcomes for patients with difficult-to-treat malignancies across the 7MM.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Radioligand Therapies
4. Key Events
5. Radioligand Therapies Market Overview At A Glance
6. Background And Overview
7. Target Population
8. Radioligand Therapies Marketed Drugs
9. Radioligand Therapies Emerging Drugs
10. Radioligand Therapies: The 7MM Analysis
11. Radioligand Therapy Unmet Needs
12. SWOT Analysis
13. KOL Views
14. Radioligand Therapy Market Access and Reimbursement
15. Appendix
16. Delveinsight Capabilities
17. Disclaimer
18. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=novartis-radioligand-therapies-pipeline-and-strategic-acquisitions-key-drivers-behind-radioligand-therapies-market-exponential-growth-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novartis' Radioligand Therapies Pipeline and Strategic Acquisitions: Key Drivers Behind Radioligand Therapies Market Exponential Growth Through 2034 | DelveInsight here
News-ID: 4019190 • Views: …
More Releases from ABNewswire
Distill Laser Clinic Oakville Launches Fall "Glow & Restore" Promotion Featuring …
Oakville, ON - Sep 12, 2025 - Distill Laser Clinic's Oakville location is excited to launch its exclusive "Glow & Restore" promotion this fall, combining the powerful skin-rejuvenating effects of Morpheus8 treatments with premium SkinCeuticals skincare products.
Image: https://www.abnewswire.com/upload/2025/09/1a41c667b0e8dc421d3f300fd85ce8d1.jpg
As the crisp autumn season approaches, many clients look to refresh and revitalize their skin following summer, and Distill's Oakville clinic [https://www.distilllaserclinic.com/distill-laser-clinic-oakville/] is answering that call with an innovative, dual-offer initiative. Morpheus8, a…
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
More Releases for Radioligand
Radioligand Therapies Market Dynamics Indicate Upward Trajectory Through 2034, R …
DelveInsight's "Radioligand Therapies Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Radioligand Therapies, historical and forecasted epidemiology as well as the Radioligand Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Radioligand Therapies, offering comprehensive insights into the Radioligand Therapies revenue trends, prevalence, and treatment landscape. The…
Radioligand Therapy Market Study Analysis with Forecast to 2034
The Radioligand Therapy Market Size is valued at USD 2.31 Billion in 2024 and is predicted to reach USD 8.33 Billion by the year 2034 at a 12.1% CAGR during the forecast period for 2025-2034.
Global Radioligand Therapy Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1281
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Radioligand Therapy market…
Radioligand Therapy Market Deep Research Report with Forecast to 2034
The Radioligand Therapy Market Size is valued at USD 2.31 Billion in 2024 and is predicted to reach USD 8.33 Billion by the year 2034 at a 12.1% CAGR during the forecast period for 2025-2034.
Global Radioligand Therapy Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1281
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Radioligand Therapy market…
Radioligand Therapy Market is on an Upward Growth Curve
The Radioligand Therapy Market Size is valued at USD 1.8 Billion in 2023 and is predicted to reach USD 2.8 Billion by the year 2031 at a 5.60% CAGR during the forecast period for 2024-2031.
Global Radioligand Therapy Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1281
Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Radioligand Therapy market…
Radioligand Therapy Market Was Dominated by United States
The total size of the radioligand therapy market was USD 7,785.6 million in 2021, and powering at a rate of 5.9% during the coming years, it will reach USD 13,073.9 million by 2030, as stated in one of its reports by P&S Intelligence.
Browse full report at: https://www.psmarketresearch.com/market-analysis/radioligand-therapy-market
The advances in nuclear medicine will be the main enabler for radiopharmaceuticals to get a major place in medicine. These are being progressively used…
Radioligand Therapy Market To Reach $13,073.9 Million by 2030
The major drivers in the global radioligand therapy market are skyrocketing demand for highly efficient drugs and surging investments in research and development of cancer treatment. In 2021, the market was valued at $7,785.6 million, and it is predicted to touch $13,073.9 million by 2030. Moreover, the market will witness an approximately 6% CAGR from 2021 to 2030. Additionally, this market had witnessed magnificent growth in the count of FDA-approved…
